Federal Register Notice: FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet 5/1, from 8 a.m. to 5:30 p.m. at the Hilton Washington DC North/Gaithersburg, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD. The committee will discuss GlaxoSmithKline’s efficacy supplement to an NDA for the approved product Advair Diskus 500/50 (fluticasone propionate/salmeterol inhalation powder) for the proposed indication of increased survival and reduced exacerbations in patients with chronic obstructive pulmonary disease. Contact Teresa Watkins, (301) 827-7001. To view this notice, click here.